Malaria chemotherapy.
Most malaria control strategies today depend on safe and effective drugs, as they have done for decades. But sensitivity to chloroquine, hitherto the workhorse of malaria chemotherapy, has rapidly declined throughout the tropics since the 1980s, and this drug is now useless in many high-transmission areas. New options for resource-constrained governments are few, and there is growing evidence that the burden from malaria has been increasing, as has malaria mortality in Africa. In this chapter, we have tried to outline the main pharmacological properties of current drugs, and their therapeutic uses and limitations. We have summarised the ways in which these drugs are employed, both in the formal health sector and in self-medication. We have briefly touched on the limitations of current drug development, but have tried to pick out a few promising drugs that are under development. Given that Plasmodium falciparum is the organism that kills, and that has developed multi-drug resistance, we have tended to focus upon it. Similarly, given that around 90% of global mortality from malaria occurs in Africa, there is the tendency to dwell on this continent. We give no apology for placing our emphasis upon the use of antimalarial drugs in endemic populations rather than their use for prophylaxis in travellers.
Winstanley
Peter
P
Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool L69 3GE, UK.
Ward
Stephen
S
D000349:Africa; D000818:Animals; D000962:Antimalarials / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D019468:Disease Management; D015195:Drug Design; D005260:Female; D006801:Humans; D008288:Malaria / Q000188:drug therapy* / Q000517:prevention & control*; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000517:prevention & control; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000188:drug therapy
D000962:Antimalarials